Esperion to Participate in Fireside Chat at the 16th Annual Needham Healthcare Conference
March 28, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
Fireside Chat on Tuesday, April 4, 2017 at 1:40 p.m. Eastern Time ANN ARBOR, Mich., March 28, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company...
Esperion Announces FDA Confirmation Regarding Regulatory Pathway to Approval for an LDL-C Lowering Indication for Bempedoic Acid
March 20, 2017 07:30 ET
|
Esperion Therapeutics, Inc.
- Global Pivotal Phase 3 Program Design Can Support Approval for an LDL-C Lowering Indication - - Proposed LDL-C Lowering Indication Will Include Patients with High CVD Risk, Specifically Those...
Esperion Announces Initiation of Phase 2 Triplet Oral Therapy Study of Bempedoic Acid/Ezetimibe/Atorvastatin
March 07, 2017 08:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 07, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary,...
Esperion Announces Oral Presentation on Genetic Validation of ATP Citrate Lyase Inhibition at the American College of Cardiology 66th Annual Scientific Session
March 06, 2017 08:30 ET
|
Esperion Therapeutics, Inc.
Company to Host Webcast on Sunday, March 19, 2017 at 5:30 p.m. Eastern Time ANN ARBOR, Mich., March 06, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management...
Esperion Provides Bempedoic Acid Development Program Update; Reports Fourth Quarter and Full Year 2016 Financial Results
February 22, 2017 07:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary,...
Esperion to Participate in Fireside Chat at RBC Capital Markets Global Healthcare Conference
February 15, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
Fireside Chat Webcast on Wednesday, February 22, 2017 at 8:00 a.m. Eastern Time ANN ARBOR, Mich., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management...
Esperion Completes Enrollment of Pivotal Phase 3 Long-Term Safety and Tolerability Study of Bempedoic Acid in Patients with Hypercholesterolemia
January 25, 2017 08:05 ET
|
Esperion Therapeutics, Inc.
Approximately 2,000 Patients Enrolled Ahead of Schedule Following Study Expansion in October 2016Global Study Enrolled Patients with Hypercholesterolemia with ASCVD and/or HeFH at High CVD...
Esperion Announces Initiation of Global Cardiovascular Outcomes Trial for Bempedoic Acid
January 09, 2017 08:05 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing complementary oral therapies for...
Esperion Announces Initiation of Three Pivotal Phase 3 Studies for Bempedoic Acid
January 08, 2017 16:00 ET
|
Esperion Therapeutics, Inc.
Global Phase 3 Program Top-Line Results Expected Mid-2018 ANN ARBOR, Mich., Jan. 08, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on...
Esperion Therapeutics Announces Publication of Definitive Paper on Bempedoic Acid Mechanism of Action in Nature Communications
November 28, 2016 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment of...